Clinical trial
Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired…
NCT00080496 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00080496 |
|---|---|
| Title | Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia |
| Official title | A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Tigecycline Vs Imipenem/Cilastatin For The Treatment Of Subjects With Nosocomial Pneumonia |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bacterial Pneumonia |
| Intervention type | Drug |
| Interventions | Tigecycline, Imipenem, Cilastatin |
| Enrollment | 430 |
| Start date | Jul 1, 2003 |
| Completion | Dec 1, 2006 |
| First posted | Apr 7, 2004 |
| Last update posted | Aug 4, 2008 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: